Ph.D. - Director Compliance & Validation
Eric graduated in Biomedical Sciences as Toxicologist, finalised the Postdoctoral Program Toxicology (registered Toxicologist) and completed his PhD in Pharmacology at the University of Nijmegen. After a Research Fellowship at the toxicology labs of NV Organon, he continued his further career in the Research orientated Pharmaceutical and Biopharmaceutical industry until to date, building more than 22 years experience in setting up and managing drug development programs from scouting & licensing of new technologies to managing start-up companies.
Before joining Xendo he was Licensing Manager for the research departments of NV Organon, and thereafter joined the management team of Amsterdam Molecular Therapeutics during its initiation (now UniQure) as Executive VP Business Development also statutory responsible for the GMP unit for viral vectors. Subsequently, he founded and was Managing Director of AMCAS, a company commercialising drug screening models containing a functional human immune system. He shifted to Pantarhei Bioscience as CBO and later on as CEO of its daughter company Pantarhei Oncology, companies developing drugs in reproductive medicine and endocrine cancer. In parallel he was, and still is, CEO of Hep-Art Medical Devices, a company developing a Bioartificial Liver System. Interim, he was CEO of Arthrogen (gene therapy in rheumatoid arthritis) during the very same period. Eric further enjoyed his Board Membership of the Dutch Biopharmaceutical Society Biofarmind during a period of 3 years up to its merger to HollandBio.
In 2017 he joined Xendo and was appointed Director Compliance & Validation as of 1 April.